Business
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million
Additional funding provides financial flexibility to expand opportunistic share repurchases and support strategic and operational initiatives NEW YORK, March
About this update from Tg Therapeutics, Inc.
[{"type":"text","content":"Additional funding provides financial flexibility to expand opportunistic share repurchases and support strategic and operational initiatives\nNEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (“TG” or “the Company”), (NASDAQ: TGTX), today announced that it has entered into a new five-year, $750 million senior secured credit facility with funds managed by Blue Owl Capital (“Blue Owl”). As part of the transaction, the Company will repay its outstanding $250 million senior secured credit facility, resulting in a net raise of $500 million in non-dilutive capital. The new facility also provides for up to an additional $250 million of incremental capital, for a total facility size of up to $1 billion, available at the mutual discretion of TG and Blue Owl. In connection with the new facility, the Company’s Board of Directors authorized an increase to its share repurchase program from $100 million to $300 million. As of March 18, 2026, the Company has repurchased approximately $38 million of common stock under the prior and existing share repurchase program at an average price of $28.98 per share. Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, “We are pleased to announce this expanded credit facility with funds managed by Blue Owl, which significantly enhances our financial position with increased scale and improved terms compared to our prior facility. This financing builds on our cash flow positive business and provides substantial non-dilutive capital to support opportunistic share repurchases and business development, while continuing to invest in the growth of BRIUMVI and advancement of our pipeline.” Weiss continued, “The expansion of our share repurchase program underscores our confidence in our business and our commitment to delivering long-term shareholder value. We appreciate Blue Owl’s continued relationship and support.” “TG Therapeutics continues to demonstrate strong commercial execution with BRIUMVI and a disciplined approach to growth,” said Sandip Agarwala, Managing Director and Head of Life Sciences at Blue Owl. “We are pleased to deepen our relationship with TG through this expanded facility and support the Company as it continues to advance its strategic initiatives.”Additional details regarding the credit facility will be filed with the Securities and Exchange Co...